Dr. Marta Kováčová

Dr. Marta Kováčová is a consultant medical oncologist at the National Cancer Institute Slovakia in Bratislava, Slovakia's dedicated national cancer treatment and research centre. With 16 years of specialist experience and a PhD, she specialises in lung oncology, immunotherapy, and precision medicine — areas that represent the leading edge of contemporary cancer treatment. The National Cancer Institute Slovakia is the country's foremost oncology institution, providing comprehensive cancer diagnostic, treatment, and research services aligned with European oncology standards. Dr. Kováčová's expertise in immunotherapy and precision oncology reflects her engagement with the most advanced and rapidly evolving areas of modern cancer medicine.

Dr. Kováčová completed her MD at Comenius University Faculty of Medicine in Bratislava and undertook oncology residency and specialist training at the National Cancer Institute Slovakia. She earned her PhD, contributing peer-reviewed research to oncology. Her medical oncology training encompassed systemic cancer therapy including chemotherapy, targeted therapy, and immunotherapy, with particular focus on thoracic oncology. She has completed advanced training in immunotherapy management — including management of immune-related adverse events — and molecular tumour profiling for precision medicine treatment selection. She participates in ESMO, IASLC, and Slovak oncology CME programmes.

Dr. Kováčová's oncology practice centres on thoracic malignancies and the application of precision oncology approaches to cancer treatment. Her lung oncology expertise covers non-small cell lung cancer (NSCLC) and small cell lung cancer, applying molecular profiling (EGFR, ALK, ROS1, KRAS, BRAF, PD-L1 status) to guide targeted therapy and immunotherapy selection. She initiates and monitors immune checkpoint inhibitor therapy (pembrolizumab, nivolumab, atezolizumab) and manages immune-related adverse events. Her precision medicine practice involves molecular tumour board participation, next-generation sequencing interpretation, and identification of actionable mutations for targeted agent matching. She also manages mesothelioma, thymic tumours, and other thoracic malignancies.

National Cancer Institute Slovakia is Slovakia's national oncology centre, providing cancer care aligned with European standards through ESMO-accredited pathways. International patients seeking oncology consultations, second opinions on lung cancer treatment plans, or access to clinical trials may access the institute. Slovakia's EU membership ensures high regulatory and quality standards. Dr. Kováčová consults in Slovak, Czech, and English. Bratislava is conveniently located with good access from Vienna, Prague, and Budapest. The institute can provide English-language oncology reports and second opinion consultations for international patients and overseas physicians.

Dr. Kováčová has been recognised by the Slovak Oncological Society and the National Cancer Institute Slovakia for her contributions to lung oncology and immunotherapy. Her PhD from Comenius University reflects peer-evaluated research contribution. She has participated in international lung cancer clinical trials and presented research at ESMO Congress and the International Association for the Study of Lung Cancer (IASLC). She has been commended for advancing precision oncology capabilities at the National Cancer Institute Slovakia and for her role in tumour molecular board activities.